Long-Term Incidence and Details of Bleeding Events After Everolimus-Eluting Stent Implantation　― 7–8-Year Outcomes ―-Reference-Cited by-同舟云学术

Long-Term Incidence and Details of Bleeding Events After Everolimus-Eluting Stent Implantation　― 7–8-Year Outcomes ―

Published:2019-10-25 Issue:11 Volume:83 Page:2242-2249
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Miura Katsuya¹,Shimada Takenobu¹,Ohya Masanobu¹,Murai Ryosuke¹,Amano Hidewo¹,Kubo Shunsuke¹,Tada Takeshi¹,Tanaka Hiroyuki¹,Fuku Yasushi¹,Goto Tsuyoshi¹,Kadota Kazushige¹

Affiliation:

1. Department of Cardiology, Kurashiki Central Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/83/11/83_CJ-19-0494/_pdf

Reference36 articles.

1. 1. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: Final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 2013; 6: 1263–1266.

2. 2. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6: 914–922.

3. 3. Mehran R, Giustino G, Baber U. DAPT duration after DES: What is the “mandatory” duration? J Am Coll Cardiol 2015; 65: 1103–1106.

4. 4. Yeh RW, Mauri L, Kereiakes DJ. Dual antiplatelet therapy duration following coronary stenting. J Am Coll Cardiol 2015; 65: 787–790.

5. 5. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015; 65: 2211–2221.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma growth factors maintain constitutive translation in platelets to regulate reactivity and thrombotic potential;Blood Advances;2024-03-26

2. Gastrointestinal and Intracranial Bleeding Events After Second-Generation Drug-Eluting Stent Implantation　― Their Association With High Bleeding Risk, Predictors, and Clinical Outcomes ―;Circulation Journal;2022-04-25

3. Incidence and predictors of serious bleeding during long-term follow-up after acute coronary syndrome in a population-based cohort study;Scientific Reports;2021-11-09

4. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting;JACC: Cardiovascular Interventions;2021-11

5. Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable;Journal of Cardiology;2021-08